| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| GA-Binding Protein Transcription Factor | 13 | 2016 | 16 | 2.030 |
Why?
|
| DNA-Binding Proteins | 13 | 2011 | 1151 | 1.190 |
Why?
|
| Transcription Factors | 16 | 2014 | 1471 | 1.140 |
Why?
|
| Myelopoiesis | 3 | 2011 | 14 | 0.890 |
Why?
|
| Promoter Regions, Genetic | 15 | 2007 | 652 | 0.870 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2016 | 318 | 0.830 |
Why?
|
| CD18 Antigens | 7 | 2006 | 30 | 0.820 |
Why?
|
| Myeloid Cells | 5 | 2008 | 89 | 0.770 |
Why?
|
| Tretinoin | 3 | 2008 | 49 | 0.740 |
Why?
|
| Sp1 Transcription Factor | 6 | 2004 | 21 | 0.710 |
Why?
|
| Trans-Activators | 4 | 2016 | 300 | 0.620 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2013 | 68 | 0.480 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2014 | 167 | 0.480 |
Why?
|
| Monocytes | 3 | 2012 | 345 | 0.470 |
Why?
|
| Precision Medicine | 1 | 2014 | 102 | 0.420 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2014 | 300 | 0.420 |
Why?
|
| CD11c Antigen | 1 | 2012 | 8 | 0.410 |
Why?
|
| Gene Expression Regulation | 9 | 2016 | 1554 | 0.410 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 73 | 0.400 |
Why?
|
| Transcription, Genetic | 7 | 2005 | 841 | 0.390 |
Why?
|
| Leukocytosis | 1 | 2012 | 11 | 0.390 |
Why?
|
| Protein Kinases | 1 | 2013 | 142 | 0.380 |
Why?
|
| Mitochondria | 1 | 2014 | 344 | 0.360 |
Why?
|
| Cell Differentiation | 6 | 2016 | 1304 | 0.340 |
Why?
|
| Receptors, Retinoic Acid | 3 | 2008 | 55 | 0.330 |
Why?
|
| Membrane Proteins | 3 | 2012 | 850 | 0.330 |
Why?
|
| Dendritic Cells | 1 | 2012 | 515 | 0.320 |
Why?
|
| Cell Cycle | 2 | 2013 | 383 | 0.320 |
Why?
|
| Mice | 12 | 2016 | 10309 | 0.260 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2006 | 9 | 0.260 |
Why?
|
| Animals | 18 | 2016 | 19683 | 0.260 |
Why?
|
| Leukemia | 1 | 2005 | 57 | 0.230 |
Why?
|
| Base Sequence | 12 | 2000 | 1302 | 0.230 |
Why?
|
| Hematopoiesis | 1 | 2004 | 120 | 0.210 |
Why?
|
| Chromatin | 2 | 2008 | 601 | 0.200 |
Why?
|
| Cell Line | 8 | 2007 | 1984 | 0.200 |
Why?
|
| Binding Sites | 7 | 2006 | 881 | 0.190 |
Why?
|
| Cells, Cultured | 6 | 2014 | 2095 | 0.190 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2016 | 276 | 0.190 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2016 | 145 | 0.190 |
Why?
|
| Leukocyte Elastase | 2 | 1999 | 13 | 0.180 |
Why?
|
| Granulocytes | 3 | 2016 | 70 | 0.170 |
Why?
|
| Transcriptional Activation | 4 | 2006 | 187 | 0.170 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 1997 | 13 | 0.170 |
Why?
|
| Heart Neoplasms | 1 | 2000 | 31 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 1 | 2000 | 59 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2016 | 402 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 2 | 2012 | 196 | 0.160 |
Why?
|
| Pseudogenes | 1 | 1999 | 12 | 0.160 |
Why?
|
| Humans | 28 | 2019 | 59550 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1999 | 22 | 0.160 |
Why?
|
| Paclitaxel | 2 | 1997 | 90 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 1997 | 87 | 0.160 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 33 | 0.160 |
Why?
|
| Mice, Knockout | 3 | 2014 | 2000 | 0.160 |
Why?
|
| Fibroblasts | 2 | 2014 | 378 | 0.160 |
Why?
|
| Nuclear Proteins | 3 | 2000 | 750 | 0.150 |
Why?
|
| Transfection | 6 | 2007 | 675 | 0.150 |
Why?
|
| Molecular Sequence Data | 9 | 2000 | 1953 | 0.150 |
Why?
|
| Immunoblotting | 3 | 2016 | 190 | 0.140 |
Why?
|
| Gene Expression | 3 | 2013 | 810 | 0.140 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1206 | 0.130 |
Why?
|
| Mutagenesis | 1 | 1997 | 128 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2019 | 345 | 0.130 |
Why?
|
| Genes, p53 | 1 | 1996 | 52 | 0.130 |
Why?
|
| DNA | 4 | 1999 | 806 | 0.130 |
Why?
|
| Survival Rate | 2 | 2016 | 801 | 0.130 |
Why?
|
| Leukocytes | 2 | 2012 | 97 | 0.130 |
Why?
|
| Burkitt Lymphoma | 1 | 2016 | 57 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 497 | 0.120 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2012 | 46 | 0.120 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 142 | 0.120 |
Why?
|
| Neoplasm Proteins | 2 | 2012 | 278 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1996 | 147 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 325 | 0.120 |
Why?
|
| Genes, Mitochondrial | 1 | 2014 | 4 | 0.110 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 23 | 0.110 |
Why?
|
| Algorithms | 1 | 2019 | 980 | 0.110 |
Why?
|
| RNA, Ribosomal | 1 | 2014 | 53 | 0.110 |
Why?
|
| Antigens, CD | 2 | 1992 | 343 | 0.110 |
Why?
|
| RNA, Untranslated | 1 | 2014 | 101 | 0.110 |
Why?
|
| Deoxycytidine | 2 | 2011 | 40 | 0.110 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 207 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2012 | 645 | 0.110 |
Why?
|
| Mutation | 3 | 2012 | 2458 | 0.100 |
Why?
|
| Protein Binding | 5 | 2004 | 1555 | 0.100 |
Why?
|
| Imatinib Mesylate | 1 | 2013 | 33 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 25 | 0.100 |
Why?
|
| Signal Transduction | 5 | 2016 | 2901 | 0.100 |
Why?
|
| Apoptosis | 2 | 2014 | 1033 | 0.100 |
Why?
|
| Benzamides | 1 | 2013 | 63 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2014 | 271 | 0.100 |
Why?
|
| Piperazines | 1 | 2013 | 74 | 0.100 |
Why?
|
| Receptors, Leukocyte-Adhesion | 1 | 1992 | 3 | 0.100 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 289 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 4 | 2003 | 450 | 0.100 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2006 | 103 | 0.100 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2008 | 18 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2013 | 132 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2008 | 259 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 170 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-ets | 4 | 2002 | 19 | 0.090 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2011 | 1 | 0.090 |
Why?
|
| DNA Probes | 3 | 1998 | 35 | 0.090 |
Why?
|
| Antigens, CD20 | 1 | 2011 | 14 | 0.090 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2011 | 8 | 0.090 |
Why?
|
| CD11b Antigen | 1 | 2011 | 19 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 359 | 0.090 |
Why?
|
| Histones | 1 | 2014 | 462 | 0.090 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 88 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 50 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 1996 | 586 | 0.090 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 234 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2009 | 193 | 0.080 |
Why?
|
| Doxorubicin | 3 | 2011 | 97 | 0.080 |
Why?
|
| Sarcoma, Kaposi | 1 | 2010 | 15 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2005 | 474 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 39 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 2 | 2002 | 197 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 83 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 138 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2016 | 248 | 0.080 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 3 | 2016 | 27 | 0.080 |
Why?
|
| Precipitin Tests | 2 | 2006 | 76 | 0.080 |
Why?
|
| Antigens, Differentiation | 1 | 1989 | 137 | 0.080 |
Why?
|
| Cell Nucleus | 4 | 2016 | 608 | 0.080 |
Why?
|
| Peroxidase | 1 | 1989 | 70 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 194 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 648 | 0.070 |
Why?
|
| Retinoids | 1 | 2008 | 12 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2008 | 15 | 0.070 |
Why?
|
| Leukemia, Myeloid | 1 | 2008 | 32 | 0.070 |
Why?
|
| DNA Primers | 2 | 1999 | 289 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 628 | 0.070 |
Why?
|
| Phenotype | 1 | 2011 | 1139 | 0.070 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2008 | 54 | 0.070 |
Why?
|
| DNA Polymerase I | 1 | 2007 | 5 | 0.070 |
Why?
|
| Thymidylate Synthase | 1 | 2007 | 6 | 0.070 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2007 | 7 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 29 | 0.070 |
Why?
|
| Cyclins | 1 | 2007 | 40 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 52 | 0.070 |
Why?
|
| NIH 3T3 Cells | 1 | 2007 | 95 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 180 | 0.070 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2007 | 43 | 0.070 |
Why?
|
| Integrases | 1 | 2007 | 36 | 0.070 |
Why?
|
| Vincristine | 2 | 2011 | 25 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2009 | 942 | 0.070 |
Why?
|
| U937 Cells | 1 | 2006 | 8 | 0.060 |
Why?
|
| Cyclophosphamide | 2 | 2011 | 75 | 0.060 |
Why?
|
| Retinoid X Receptors | 1 | 2006 | 14 | 0.060 |
Why?
|
| Prednisone | 2 | 2011 | 85 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 354 | 0.060 |
Why?
|
| Retroviridae Proteins, Oncogenic | 2 | 1995 | 3 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 1999 | 381 | 0.060 |
Why?
|
| Middle Aged | 7 | 2019 | 16377 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 448 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2006 | 255 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 656 | 0.060 |
Why?
|
| Sp3 Transcription Factor | 1 | 2004 | 2 | 0.060 |
Why?
|
| Protein Biosynthesis | 2 | 1999 | 297 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1995 | 65 | 0.050 |
Why?
|
| Kenya | 2 | 2016 | 79 | 0.050 |
Why?
|
| Receptor Cross-Talk | 1 | 2003 | 10 | 0.050 |
Why?
|
| Response Elements | 1 | 2003 | 43 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2002 | 31 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 1367 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1143 | 0.050 |
Why?
|
| Male | 6 | 2019 | 27838 | 0.050 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2002 | 39 | 0.050 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2002 | 87 | 0.050 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2016 | 64 | 0.040 |
Why?
|
| Disease Progression | 2 | 2019 | 1119 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2012 | 186 | 0.040 |
Why?
|
| Lactoferrin | 1 | 2000 | 36 | 0.040 |
Why?
|
| Remission Induction | 2 | 1997 | 137 | 0.040 |
Why?
|
| Dyspnea | 1 | 2000 | 116 | 0.040 |
Why?
|
| Nerve Growth Factors | 1 | 1999 | 26 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 5141 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 1999 | 84 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 1999 | 284 | 0.040 |
Why?
|
| Aged | 4 | 2019 | 13456 | 0.040 |
Why?
|
| Glycoproteins | 1 | 1999 | 187 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 1997 | 44 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 1997 | 11 | 0.030 |
Why?
|
| Casein Kinase II | 1 | 1997 | 16 | 0.030 |
Why?
|
| Deoxyribonuclease HindIII | 1 | 1997 | 1 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 939 | 0.030 |
Why?
|
| Female | 5 | 2019 | 30824 | 0.030 |
Why?
|
| Multigene Family | 1 | 1997 | 92 | 0.030 |
Why?
|
| Dimerization | 1 | 1997 | 144 | 0.030 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1997 | 25 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 178 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 16 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1997 | 65 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1034 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1997 | 96 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 1997 | 69 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 3240 | 0.030 |
Why?
|
| DNA Footprinting | 1 | 1995 | 17 | 0.030 |
Why?
|
| Exons | 1 | 1996 | 191 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1995 | 26 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 191 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1995 | 98 | 0.030 |
Why?
|
| Forecasting | 1 | 1996 | 222 | 0.030 |
Why?
|
| Calcitriol | 1 | 1995 | 24 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 162 | 0.030 |
Why?
|
| Cell Death | 1 | 1996 | 271 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 396 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 195 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1996 | 394 | 0.030 |
Why?
|
| Phosphorylation | 1 | 1997 | 884 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 410 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 587 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 1998 | 482 | 0.030 |
Why?
|
| Massachusetts | 1 | 2019 | 2025 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 1997 | 331 | 0.030 |
Why?
|
| CD11 Antigens | 2 | 1992 | 15 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 26 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2012 | 31 | 0.030 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 25 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 808 | 0.030 |
Why?
|
| Cytarabine | 1 | 2012 | 32 | 0.030 |
Why?
|
| Genomic Library | 1 | 1992 | 10 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1992 | 51 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 1992 | 32 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 1992 | 18 | 0.020 |
Why?
|
| Quinazolines | 1 | 1992 | 21 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 228 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1992 | 45 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 1495 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 846 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 38 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 57 | 0.020 |
Why?
|
| Utrophin | 2 | 2002 | 4 | 0.020 |
Why?
|
| Rituximab | 1 | 2011 | 80 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 1798 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 243 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1992 | 211 | 0.020 |
Why?
|
| Vinblastine | 1 | 2010 | 18 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2378 | 0.020 |
Why?
|
| Bleomycin | 1 | 2010 | 32 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2011 | 5304 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2009 | 32 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 328 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2012 | 6112 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 223 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 99 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2009 | 365 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 554 | 0.020 |
Why?
|
| Adult | 3 | 2012 | 15726 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 1992 | 1469 | 0.020 |
Why?
|
| Child | 1 | 2016 | 4209 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 5002 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2344 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 5860 | 0.020 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2000 | 6 | 0.010 |
Why?
|
| Luciferases | 1 | 2000 | 106 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1999 | 16 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1999 | 48 | 0.010 |
Why?
|
| Myeloblastin | 1 | 1999 | 14 | 0.010 |
Why?
|
| Drosophila | 1 | 2002 | 422 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 490 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 691 | 0.010 |
Why?
|
| Neutropenia | 1 | 1997 | 62 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 52 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 1995 | 41 | 0.010 |
Why?
|
| Receptors, Calcitriol | 1 | 1995 | 33 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1995 | 52 | 0.010 |
Why?
|
| Rats | 1 | 1999 | 1909 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 1999 | 678 | 0.010 |
Why?
|
| Cell Division | 1 | 1995 | 443 | 0.010 |
Why?
|
| Ploidies | 1 | 1992 | 2 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1992 | 21 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 148 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1992 | 526 | 0.010 |
Why?
|
| Kinetics | 1 | 1992 | 751 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1997 | 1520 | 0.010 |
Why?
|
| Time Factors | 1 | 1992 | 3624 | 0.000 |
Why?
|